Home > Insider Trading > Filing (0000947871-23-000778)

Filing Details

Accession Number:: 0000947871-23-000778
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-07-24 16:40:42
Reporting Period:: 2023-07-20

Accepted Time:: 2023-07-24 16:40:42
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1764974	Turnstone Biologics Corp.	TSBX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1537370	Rishi Gupta	C/O Turnstone Biologics Corp. 9310 Athena Circle, Suite 300 La Jolla CA 92037		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-07-20	2,682,599	$0.00	2,682,599	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2023-07-20	416,666	$12.00	3,099,265	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B-1 Preferred Stock	Disposition	2023-07-20	937,372	$0.00	937,372	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2023-07-20	1,249,829	$0.00	1,249,829	$0.00
Common Stock	Series C Preferred Stock	Disposition	2023-07-20	266,240	$0.00	266,240	$0.00
Common Stock	Series D Preferred Stock	Disposition	2023-07-20	229,158	$0.00	229,158	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-to-one basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.
These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI.
Each of the Reporting Person, OrbiMed Advisors and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP VI, or OrbiMed Advisors is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.